Journal ArticleDOI
Comparative Effect of Proton-Pump Inhibitors on the Success of Triple and Quadruple Therapy for Helicobacter pylori Infection
Doron Boltin,Zohar Levi,Rachel Gingold-Belfer,Hemda Schmilovitz-Weiss,Tzippy Shochat,Ram Dickman,Tsachi Tsadok Perets,Iris Dotan,Yaron Niv +8 more
Reads0
Chats0
TLDR
Esomeprazole is more beneficial than other PPIs for H. pylori eradication among subjects receiving quadruple therapy, and independent predictors of treatment success included older age and quadruple Therapy.Abstract:
Introduction Suppression of gastric acid secretion with proton-pump inhibitors (PPI) is an integral part of the treatment of Helicobacter pylori infection. Esomeprazole has been shown to be superior to other PPIs when used in the context of triple therapy; however, comparative data for PPI efficacy in quadruple therapy are lacking. Current guidelines recommend H. pylori eradication with quadruple therapy in areas with high clarithromycin resistance. Objective To determine whether esomeprazole is more effective than other PPIs in the context of quadruple therapy for H. pylori eradication. Methods We retrospectively identified 25- to 60-year-old subjects with a positive 13C-urea breath test and no prior laboratory or endoscopic test for H. pylori infection. Pharmacy dispensation data were retrieved. Results A total of 7,896 subjects including 2,856 (36.2%) males, aged 40.4 ± 10.6 years, were identified. Of those, 78.1% received omeprazole, 20.1% received lansoprazole, 1.5% received esomeprazole, and 0.34% received pantoprazole together with antibiotics for H. pylori eradication. Esomeprazole was associated with a greater proportion of successful eradication (85.0 vs. 77.5%, esomeprazole vs. omeprazole, OR 1.64; 95% CI 0.99-2.72; p = 0.05). A nonsignificant trend favored esomeprazole over omeprazole among subjects receiving quadruple therapy (90.0 vs. 82.0%, respectively, OR 1.98; 95% CI 0.68-5.72; p = 0.16). Independent predictors of treatment success included older age and quadruple therapy. Conclusion Esomeprazole is more beneficial than other PPIs for H. pylori eradication. Studies with larger subgroups are necessary to confirm our findings among subjects receiving quadruple therapy.read more
Citations
More filters
Journal ArticleDOI
Review - Treatment of Helicobacter pylori infection 2020
TL;DR: This review summarizes important studies regarding Helicobacter pylori therapy published from April 2019 to April 2020 that involve studies assessing antibiotic resistance, and there is also growing momentum behind the utility of vonoprazan as an alternative to proton pump inhibitor (PPI) therapy and also bismuth‐based regimens as a first‐line regimen.
Journal ArticleDOI
Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China
TL;DR: A retrospective study on 264 outpatients who were diagnosed with H. pylori-associated chronic gastritis and peptic ulcer disease between January and December 2015 at a large tertiary hospital in China found patients with duodenal ulcers had a higher H.pylori eradication rate than those with other lesions.
Journal ArticleDOI
Relative Potency of Proton-Pump Inhibitors
TL;DR: Various proton-pump inhibitors (PPIs) are used in different doses to achieve similar clinical results and ideal dosing regimens are suggested.
Journal ArticleDOI
The efficacy of bismuth quadruple therapy, sequential therapy, and hybrid therapy as a first-line regimen for Helicobacter pylori infection compared with standard triple therapy
TL;DR:
Journal ArticleDOI
Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti- Helicobacter pylori Treatment in Real World Clinical Practice.
Kuo-Tung Hung,Shih-Cheng Yang,Cheng-Kun Wu,Cheng-Kun Wu,Hsing-Ming Wang,Chih-Chien Yao,Chih-Ming Liang,Chih-Ming Liang,Wei-Chen Tai,Wei-Chen Tai,Keng-Liang Wu,Keng-Liang Wu,Yuan-Hung Kuo,Yuan-Hung Kuo,Chen-Hsiang Lee,Seng-Kee Chuah,Seng-Kee Chuah +16 more
TL;DR: In this article, the authors compared the eradication rates between esomeprazole and lansoprazole-based non-bismuth concomitant quadruple therapy for first-line anti-H. pylori treatment.
References
More filters
Journal ArticleDOI
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
Peter Malfertheiner,Francis Mégraud,Colm O'Morain,Javier P. Gisbert,Ernst J. Kuipers,A. T. R. Axon,Franco Bazzoli,Antonio Gasbarrini,John Atherton,David Y. Graham,Richard H. Hunt,Paul Moayyedi,Theodore Rokkas,Massimo Rugge,Michael Selgrad,Sebastian Suerbaum,Kentaro Sugano,Emad M. El-Omar +17 more
TL;DR: This fifth edition of the Maastricht Consensus Report describes how experts from 24 countries examined new data related to H. pylori infection in the various clinical scenarios and provided recommendations on the basis of the best available evidence and relevance.
Journal ArticleDOI
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
TL;DR: Most patients will be better served by first-line treatment with bismuth quadruple therapy or concomitant therapy consisting of a PPI, clarithromycin, amoxicillin, and metronidazole.
Journal ArticleDOI
Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption
Francis Mégraud,Samuel Coenen,Ann Versporten,Manfred Kist,Manuel Lopez-Brea,Alexander M. Hirschl,Leif P. Andersen,Herman Goossens,Youri Glupczynski +8 more
TL;DR: In many countries the high rate of clarithromycin resistance no longer allows its empirical use in standard anti-H pylori regimens, so knowledge of outpatient antibiotic consumption may provide a simple tool to predict the susceptibility of H pyloris to quinolones and to macrolides and to adapt the treatment strategies.
Journal ArticleDOI
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults
Carlo A Fallone,Naoki Chiba,Naoki Chiba,Sander Veldhuyzen van Zanten,Lori A. Fischbach,Javier P. Gisbert,Richard H. Hunt,Nicola L. Jones,Craig Render,Grigorios I. Leontiadis,Paul Moayyedi,John Marshall +11 more
TL;DR: These consensus statements provide a review of the literature and specific, updated recommendations for eradication therapy in adults and recommend that all H pylori eradication regimens now be given for 14 days.
Journal ArticleDOI
A H+-Gated Urea Channel: The Link Between Helicobacter pylori Urease and Gastric Colonization
TL;DR: UreI is an inner membrane protein with six transmembrane segments as shown by in vitro transcription/translation and membrane separation Expression of ureI in Xenopus oocytes results in acid-stimulated urea uptake, with a pH profile similar to activation of cytoplasmic urease as discussed by the authors.